ACC BioRepository

ACC生物样本库

• 批准号: 10550250
• 负责人: MICHAEL D FELDMAN
• 金额: --
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-01-15 至 2025-11-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10550250
• 关键词: Address; Air Conditioning; Basic Science; Biological Specimen Banks; Biological Specimen database; Biopsy; Biopsy Specimen; Blood; Blood specimen; Cancer Center; Cancer Center Support Grant; Cell Survival; Cells; Clinical; Clinical Data; Clinical Investigator; Clinical Pathology; Clinical Protocols; Clinical Research; Clinical Sciences; Clinical Trials; Collaborations; Collection; Consent; Consultations; Coupled; DNA; Data; Development; Disease; Electronic Health Record; Ensure; Equipment and supply inventories; Excision; Farm; Freezing; Genotype; Home; Hospitals; Human; Image Guided Biopsy; Immunosuppression; Industry; Institution; Interventional radiology; Laboratories; Lead; Link; Location; Malignant Neoplasms; Medicine; Mission; Monitor; Nature; Neoplasm Circulating Cells; Normal tissue morphology; Operative Surgical Procedures; Outcome; Pathologic; Pathology; Patients; Pennsylvania; Plasma; Population; Population Sciences; Precancerous Conditions; Procedures; Process; Proteins; Protocols documentation; Pumpkins; Radiology Specialty; Recontacts; Remote management; Reporting; Research; Research Personnel; Resource Sharing; Resources; Review Committee; Sampling; Security; Serum; Services; Side; Specimen; System; Time; Tissue Banks; Tissue Sample; Tissues; Translational Research; Tumor Bank; Tumor Tissue; University Hospitals; Utilization Review; Work; biobank; blood product; cancer imaging; cancer surgery; clinical care; cohort; cost effectiveness; data management; data registry; exome; exome sequencing; exosome; extracellular vesicles; genomic data; informatics infrastructure; interest; liquid biopsy; medical schools; member; programmed cell death ligand 1; programs; prospective; radiologist; remote monitoring; repository; sample archive; sample collection; sensor; tumor; tumor DNA; tumor registry; vapor

PROJECT SUMMARY – Abramson Cancer Center BioRepository (ABR) The Abramson Cancer Center BioRepository (ABR) is a shared core laboratory comprised of four integrated components that together enable the collection of tumor and normal tissue samples from surgical resections and radiology guided biopsy (supporting clinical trials), blood collections (buffy coats, serum and plasma), and liquid biopsy (ctDNA, CTC, soluble proteins and extra-cellular vesicles). This integrated Shared Resource leverages uniformity of quality across a breadth of biosamples and enhanced efficiencies gained through use of a universal consent. The tumor tissue, blood collection and liquid biopsy material collections are supported by a new prospective universal consent allowing for collection of blood and tissue (at time of surgery), patient re-contact, “omics” study of the collected biosamples, and linkage to electronic health records for outcome- related translational research. Biosample inventory data are managed through Open Specimen, a commercial biosample database on the tissue side, and Pumpkin, a home-grown system for blood sample processing – both well-suited to handle large volume sample collections and archiving. Penn Medicine has a centralized informatics infrastructure (PennOmics v2) composed of an enterprise DataLake that combines EHR data, tumor registry data, and genomic data (germline and somatic studies) that links to stored biosample inventories across our biosample database (Open Specimen and Pumpkin) that allows for cohort exploration and requesting biosamples from these cohorts. Biosamples are stored in two new freezer farms recently constructed at the Perelman School of Medicine in either -80 freezers (buffy coats, plasma and serum) or LN2 vapor (tissue or viable cells). Both freezer farms have completely redundant air conditioning, electric and central monitoring resources including remote monitoring and alarms with O2 security sensors to support LN2 vapor storage. ABR is tightly coupled with a larger institutional biosample repository (Penn Medicine Biobank) which has grown to >60K patient blood samples, including whole exome sequencing and genotyping on >15K of these patients. The Penn Medicine Biobank is a broad effort across Penn Medicine that seeks to collect blood and tissues across a wide range of both normal patients as well as patients with a variety of diseases. The ABR Shared Resource is directed by Dr. Michael Feldman, who has been leading the tumor tissue and blood repository since its inception in 2005. Ms. Joellen Weaver, Technical Director, has worked in biobanking for 20 years. ACC members accounted for 43 of 62 investigators (69%) using this Shared Resource during the most recent reporting period (07/01/18-06/30/19). ABR has supported high-impact research, e.g. changing the fundamental understanding of immune suppression in tumors via PDL1-carrying exosomes (Chen et al., Nature, 2018). ABR facilitates access to a wide variety and number of biospecimens for ACC members across the basic, clinical, and population science Programs, addressing the changing scientific needs of ACC membership and increased research demand for tissue and blood products.

项目摘要 – 艾布拉姆森癌症中心生物存储库 (ABR) 艾布拉姆森癌症中心生物存储库 (ABR) 是一个共享核心实验室，由四个综合实验室组成 共同实现从手术切除中收集肿瘤和正常组织样本的组件 放射学引导活检（支持临床试验）、血液采集（血沉棕黄层、血清和血浆），以及 液体活检（ctDNA、CTC、可溶性蛋白和细胞外囊泡）。 利用各种生物样本的质量一致性并提高使用效率 支持肿瘤组织、血液采集和液体活检材料采集。 通过允许采集血液和组织（在手术时）的新的前瞻性普遍同意，患者 重新接触，对收集的生物样本进行“组学”研究，并链接到电子健康记录以获取结果- 相关的转化研究通过开放样本（Open Specimen）进行管理。 组织方面的生物样本数据库，以及用于血液样本处理的本土系统 Pumpkin – Penn Medicine 都非常适合处理大量样本采集和归档。 信息学基础设施 (PennOmics v2) 由结合 EHR 数据的企业 DataLake 组成， 肿瘤登记数据以及链接到存储的生物样本库存的基因组数据（种系和体细胞研究） 我们的生物样本数据库（开放样本和南瓜）允许队列探索和 要求从这些队列中获取生物样本 生物样本最近储存在两个新的冷冻库中。 佩雷尔曼医学院在 -80 冰箱（血沉棕黄层、血浆和血清）或液氮中构建 两个冷冻场都拥有完全冗余的空调、电力和蒸汽。 中央监控资源，包括带有 O2 安全传感器的远程监控和警报，以支持 LN2 ABR 与更大的机构生物样本库（Penn Medicine Biobank）紧密结合。 已发展到超过 60K 患者血液样本，包括超过 15K 的全外显子组测序和基因分型 Penn Medicine 生物库是 Penn Medicine 的一项广泛努力，旨在收集这些患者的数据。 血液和组织范围广泛，既包括正常患者，也包括患有多种疾病的患者。 ABR 共享资源由 Michael Feldman 博士领导，他一直领导肿瘤组织和 血液储存库自2005年成立以来。技术总监Joellen Weaver女士曾在生物样本库工作 20 年来，ACC 成员占 62 名研究者中的 43 名（69%）。 最近的报告期（2018 年 1 月 7 日至 2019 年 6 月 30 日），ABR 支持了高影响力的研究，例如改变 通过携带 PDL1 的外泌体对肿瘤免疫抑制的基本了解（Chen 等人， Nature，2018）。ABR 有助于 ACC 成员获取种类繁多、数量众多的生物样本。 基础、临床和人口科学项目，满足 ACC 不断变化的科学需求 会员资格以及对组织和血液制品的研究需求增加。